Perzea™ 420 mg Perzea™ 420 mg/14 mL Injection contains Pertuzumab, a monoclonal antibody that targets the HER2 receptor to slow or stop the growth of HER2-positive breast cancer cells. It is used in combination with trastuzumab and chemotherapy for the treatment of early-stage and metastatic HER2-positive breast cancer. The medicine is administered as an intravenous infusion under the supervision of an oncology specialist.

Effects & Benefits Targets HER2-positive cancer cells to inhibit tumor growth. Improves progression-free and overall survival in eligible patients. Used with trastuzumab and chemotherapy for enhanced treatment effectiveness. Helps reduce the risk of cancer recurrence in early HER2-positive breast cancer. Supports effective management of metastatic HER2-positive breast cancer. Administered under specialist supervision for optimal treatment outcomes.